share_log

Time To Worry? Analysts Are Downgrading Their WuXi AppTec Co., Ltd. (SHSE:603259) Outlook

Time To Worry? Analysts Are Downgrading Their WuXi AppTec Co., Ltd. (SHSE:603259) Outlook

是時候擔心了嗎?分析師正在下調無錫藥明康德有限公司(SHSE: 603259)展望的評級
Simply Wall St ·  03/20 19:11

The analysts covering WuXi AppTec Co., Ltd. (SHSE:603259) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Both revenue and earnings per share (EPS) estimates were cut sharply as analysts factored in the latest outlook for the business, concluding that they were too optimistic previously.

報道無錫藥明康德有限公司(SHSE: 603259)的分析師今天對今年的法定預測進行了實質性修訂,從而向股東傳遞了一定負面情緒。由於分析師將最新的業務前景考慮在內,得出結論,他們此前過於樂觀,因此收入和每股收益(EPS)的預期均大幅下調。

Following the latest downgrade, WuXi AppTec's 24 analysts currently expect revenues in 2024 to be CN¥40b, approximately in line with the last 12 months. Statutory earnings per share are presumed to accumulate 3.7% to CN¥3.40. Prior to this update, the analysts had been forecasting revenues of CN¥48b and earnings per share (EPS) of CN¥3.96 in 2024. It looks like analyst sentiment has declined substantially, with a measurable cut to revenue estimates and a real cut to earnings per share numbers as well.

繼最近的降級之後,藥明康德的24位分析師目前預計2024年的收入將達到400億元人民幣,與過去12個月大致持平。假定每股法定收益將累計3.7%至3.40元人民幣。在本次更新之前,分析師一直預測2024年的收入爲480億元人民幣,每股收益(EPS)爲3.96元人民幣。看來分析師的情緒已大幅下降,收入預期大幅下調,每股收益數字也實際下調。

earnings-and-revenue-growth
SHSE:603259 Earnings and Revenue Growth March 20th 2024
SHSE: 603259 2024 年 3 月 20 日收益和收入增長

It'll come as no surprise then, to learn that the analysts have cut their price target 27% to CN¥82.59.

因此,得知分析師已將目標股價下調27%至82.59元人民幣也就不足爲奇了。

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 1.4% by the end of 2024. This indicates a significant reduction from annual growth of 31% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 17% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - WuXi AppTec is expected to lag the wider industry.

從現在的大局來看,我們可以理解這些預測的方法之一是看看它們如何與過去的業績和行業增長預期相比較。這些估計表明,預計銷售將放緩,預計到2024年底,年化收入將下降1.4%。這表明與過去五年的31%的年增長率相比大幅下降。相比之下,我們的數據表明,在可預見的將來,預計同一行業的其他公司(有分析師報道)的收入每年將增長17%。因此,儘管預計其收入將萎縮,但這種雲並沒有帶來一線希望——預計藥明康德將落後於整個行業。

The Bottom Line

底線

The most important thing to take away is that analysts cut their earnings per share estimates, expecting a clear decline in business conditions. Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that WuXi AppTec's revenues are expected to grow slower than the wider market. After such a stark change in sentiment from analysts, we'd understand if readers now felt a bit wary of WuXi AppTec.

要了解的最重要的一點是,分析師下調了每股收益預期,預計業務狀況將明顯下降。不幸的是,分析師也下調了收入預期,行業數據表明,藥明康德的收入增長預計將慢於整個市場。在分析師的觀點發生了如此明顯的變化之後,我們可以理解讀者現在是否對藥明康德有些警惕。

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. We have estimates - from multiple WuXi AppTec analysts - going out to 2026, and you can see them free on our platform here.

即便如此,業務的長期發展軌跡對於股東的價值創造更爲重要。根據多位無錫AppTec分析師的估計,到2026年,你可以在我們的平台上免費查看。

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

尋找可能達到轉折點的有趣公司的另一種方法是使用內部人士收購的成長型公司的免費清單,跟蹤管理層是買入還是賣出。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論